Tobira Therapeutics, Inc. Research and Development Expense
Tobira Therapeutics, Inc. reported Research and Development Expense of $10.88 million for the 3-month period ending 2016-06-30, per its 10-Q filed 2016-08-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2016-08-09
- Tobira Therapeutics, Inc. research and development expense for the quarter ending 2016-06-30 was $10.88M, a 64.45% increase year-over-year.
- Tobira Therapeutics, Inc. research and development expense for the quarter ending 2016-03-31 was $8.68M, a 53.04% increase year-over-year.
- Tobira Therapeutics, Inc. research and development expense for the quarter ending 2015-12-31 was $6.29M, a 61.07% increase year-over-year.
- Tobira Therapeutics, Inc. research and development expense for the quarter ending 2015-09-30 was $6.09M, a 73.51% increase year-over-year.
- Tobira Therapeutics, Inc. research and development expense for fiscal 2015 was $24.67M, a 102.54% increase from fiscal 2014.
- Tobira Therapeutics, Inc. research and development expense for fiscal 2014 was $12.18M, a 1.87% decline from fiscal 2013.
- Tobira Therapeutics, Inc. research and development expense for fiscal 2013 was $12.41M, a 55.05% increase from fiscal 2012.
- Tobira Therapeutics, Inc. research and development expense for fiscal 2012 was $8.01M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed | Research and Development Expense 142 month | Research and Development Expense 145 month | Research and Development Expense 148 month |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-06-30 | $10.88M 10-Q · filed 2016-08-09 | $19.56M 10-Q · filed 2016-08-09 | $25.85M derived: sum of 3 quarters · filed 2016-08-09 | $31.94M derived: sum of 4 quarters · filed 2016-08-09 | |||||||
| 2016-03-31 | $8.68M 10-Q · filed 2016-05-09 | $14.97M derived: sum of 2 quarters · filed 2016-05-09 | $21.06M derived: sum of 3 quarters · filed 2016-05-09 | $27.68M derived: sum of 4 quarters · filed 2016-08-09 | |||||||
| 2015-12-31 | $6.29M 10-K · filed 2016-03-03 | $12.38M derived: sum of 2 quarters · filed 2016-03-03 | $19.00M derived: sum of 3 quarters · filed 2016-08-09 | $24.67M 10-K · filed 2016-03-03 | |||||||
| 2015-09-30 | $6.09M 10-K · filed 2016-03-03 | $12.71M derived: sum of 2 quarters · filed 2016-08-09 | $18.38M 10-Q · filed 2015-11-10 | $22.29M derived: sum of 4 quarters · filed 2016-08-09 | |||||||
| 2015-06-30 | $6.62M 10-Q · filed 2016-08-09 | $12.29M 10-Q · filed 2016-08-09 | $16.19M derived: sum of 3 quarters · filed 2016-08-09 | $19.70M derived: sum of 4 quarters · filed 2016-08-09 | |||||||
| 2015-03-31 | $5.67M 10-Q · filed 2016-05-09 | $3.65M 10-Q · filed 2015-04-29 | $9.58M derived: sum of 2 quarters · filed 2016-05-09 | $13.09M derived: sum of 3 quarters · filed 2016-05-09 | $16.18M derived: sum of 4 quarters · filed 2016-05-09 | ||||||
| 2014-12-31 | $3.91M 10-K · filed 2016-03-03 | $7.42M derived: sum of 2 quarters · filed 2016-03-03 | $10.51M derived: sum of 3 quarters · filed 2016-03-03 | $12.18M 10-K · filed 2016-03-03 | $54.93M 10-K · filed 2015-02-12 | ||||||
| 2014-09-30 | $3.51M 10-K · filed 2016-03-03 | $17.71M 10-Q · filed 2014-11-06 | $6.61M derived: sum of 2 quarters · filed 2016-03-03 | $8.27M 10-Q · filed 2015-11-10 | $49.33M 10-Q · filed 2014-11-06 | $5.09M derived: sum of 4 quarters · filed 2016-03-03 | |||||
| 2014-06-30 | $3.09M 10-K · filed 2016-03-03 | $18.50M 10-Q · filed 2014-08-11 | $4.76M 10-Q · filed 2015-08-11 | $31.62M 10-Q · filed 2014-08-11 | $1.58M derived: sum of 3 quarters · filed 2016-03-03 | $11.18M derived: sum of 4 quarters · filed 2016-03-03 | |||||
| 2014-03-31 | $1.67M 10-K · filed 2016-03-03 | $13.12M 10-Q · filed 2014-05-13 | -$1.51M derived: sum of 2 quarters · filed 2016-03-03 | $8.09M derived: sum of 3 quarters · filed 2016-03-03 | $12.40M derived: sum of 4 quarters · filed 2016-03-03 | $121.62M 10-Q · filed 2014-05-13 | |||||
| 2013-12-31 | -$3.18M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $6.42M derived: sum of 2 quarters · filed 2016-03-03 | $10.73M derived: sum of 3 quarters · filed 2016-03-03 | $12.41M 10-K · filed 2016-03-03 | $26.54M 10-K · filed 2014-03-12 | $108.50M 10-K · filed 2014-03-12 | |||||
| 2013-09-30 | $9.60M 10-Q · filed 2014-11-06 | $13.91M derived: sum of 2 quarters · filed 2014-11-06 | $15.59M 10-Q · filed 2014-11-06 | $17.13M derived: sum of 4 quarters · filed 2014-11-06 | $97.56M 10-Q · filed 2013-11-08 | ||||||
| 2013-06-30 | $4.31M 10-Q · filed 2014-08-11 | $6.05M 10-Q · filed 2014-08-11 | $7.53M derived: sum of 3 quarters · filed 2014-08-11 | $9.14M derived: sum of 4 quarters · filed 2014-08-11 | |||||||
| 2013-03-31 | $1.73M 10-Q · filed 2014-05-13 | $3.22M derived: sum of 2 quarters · filed 2014-05-13 | $4.83M derived: sum of 3 quarters · filed 2014-05-13 | ||||||||
| 2012-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-12 | $3.09M derived: sum of 2 quarters · filed 2014-03-12 | $8.01M 10-K · filed 2014-03-12 | ||||||||
| 2012-09-30 | $1.61M 10-Q · filed 2013-11-08 | $6.52M 10-Q · filed 2013-11-08 |